AHA Coding Clinic® for HCPCS - 2014 Quarter 2; For your information
Topical application of mitomycin during or following ophthalmic surgery
CMS has instructed hospital outpatient departments to only report HCPCS code J7315 , Mitomycin, ophthalmic, 0.2 mg, or HCPCS code J3490 , Unclassified drugs, for the application of mitomycin during or following ophthalmic surgery. It will only be appropriate for the hospital to report HCPCS J7315 if the hospital uses mitomycin with the trade name Mitosol ® . All other topical mitomycin should be reported with HCPCS code J3490 . Please note: HCPCS code J9280 , Injection, mitomycin, 5 mg, should not be reported by hospital outpatient departments for the topical application of mitomycin. ...
Subscribe or sign in to view the full article.
Article Overview
This article covers CMS guidance for hospital outpatient departments on reporting topical mitomycin associated with ophthalmic surgery. It is relevant to hospital coders, outpatient billing teams, and ophthalmic surgery practices that need to understand which HCPCS reporting options are referenced for this drug use scenario and what the article says about the setting-specific guidance.
Why This Topic Matters
Correctly recognizing the relevant CMS guidance helps hospital outpatient departments align their drug reporting practices with the article’s scope and avoid confusion between the topical ophthalmic use discussed and other mitomycin billing references.
What You Will Learn
- The CMS framing for topical mitomycin use in an ophthalmic surgery setting
- Which HCPCS code set is discussed for hospital outpatient reporting
- How the article distinguishes topical ophthalmic application from other mitomycin reporting references
- The setting-specific context described by the article
Who Should Read This
- Hospital outpatient coders
- Outpatient billing staff
- Revenue cycle teams
- Ophthalmology practices
- Compliance staff
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com